The Contribution of Ecstasy Dependence and Stress to Ecstasy/MDMA-Related Psychiatric Symptoms

R. Margherita Milani*,1, John Turner2 and Andy C. Parrott3

1Thames Valley University, Faculty of Health and Human Sciences, London, UK
2University of East London, Department of Psychology, London, UK
3Department of Psychology, Swansea University, Swansea, UK

Keywords: Ecstasy dependence, MDMA dependence, stress, BSI, psychiatric symptoms, anxiety, depression.

INTRODUCTION

A range of psychiatric symptoms are prevalent in regular users of recreational Ecstasy [1], and this has been linked to MDMA’s neurotoxic potential [2]. However, there are still many areas of uncertainty. This study investigated the relative contributions of dosage, perceived stress, age, gender, family psychiatric history, and Ecstasy dependency, to the psychopathological profiles of a non-clinical polydrug cohort.

Table 1. Multiple Regression Analysis Results

<table>
<thead>
<tr>
<th>BSI</th>
<th>ANOVA</th>
<th>R Square</th>
<th>Significant Predictors</th>
<th>Beta</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somatization</td>
<td>F(14,228)= 5.15, p&lt; 0.001</td>
<td>0.178</td>
<td>Age, Stress, Last time of use, E p. dependence</td>
<td>-0.320</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>Anxiety</td>
<td>F(10,218)= 5.25, p&lt;0.001</td>
<td>0.155</td>
<td>Stress, Family history, E p. dependence</td>
<td>0.286</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>Obsessive Compulsive Disorders</td>
<td>F(14,228)= 3.58, p&lt;0.001</td>
<td>0.127</td>
<td>Stress, Age, Polydrug use, E p. dependence</td>
<td>0.268</td>
<td>0.008**</td>
</tr>
<tr>
<td>Depression</td>
<td>F(12,212)= 3.27, p&lt;0.001</td>
<td>0.164</td>
<td>E p. dependence, Stress, Family History</td>
<td>0.246</td>
<td>0.001**</td>
</tr>
<tr>
<td>Interpersonal Sensitivity</td>
<td>F(8,215)= 6.014, p&lt;0.001</td>
<td>0.213</td>
<td>E dependence, Stress, Family history</td>
<td>0.231</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>Anger Hostility</td>
<td>F(13,213)= 3.83, p&lt;0.001</td>
<td>0.186</td>
<td>E p. dependence, Stress</td>
<td>0.231</td>
<td>0.003**</td>
</tr>
<tr>
<td>Phobic Anxiety</td>
<td>F(13,203)= 6.84, p&lt;0.001</td>
<td>0.226</td>
<td>Stress, Family history, E p. dependence</td>
<td>0.286</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>Paranoid Ideation</td>
<td>F(13,203)= 5.92, p&lt;0.001</td>
<td>0.238</td>
<td>E p. dependence, Stress, Last time of use, Age</td>
<td>0.367</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>Psychoticism</td>
<td>F(13,203)= 4.40, p&lt;0.001</td>
<td>0.220</td>
<td>Family history, Stress, E p. dependence</td>
<td>0.245</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>General Symptoms Distress</td>
<td>F(14,197)= 4.72, p&lt;0.001</td>
<td>0.266</td>
<td>Stress, E p. dependence, Family History</td>
<td>0.258</td>
<td>0.001**</td>
</tr>
</tbody>
</table>

E p dependence: Ecstasy psychological dependence.
*p<0.05, **P<0.01, ***p<0.001.
METHOD

The sample comprised 501 young people ranging from non-drug users to heavy Ecstasy polydrug users; participants were allocated into four groups: alcohol and/or tobacco users, polydrug users who had never taken Ecstasy, light Ecstasy polydrug users (Ecstasy on less than 20 occasions), and heavy Ecstasy polydrug users (+20 occasions). All respondents completed the Brief Symptoms Inventory (BSI), a family and personal psychiatric history questionnaire [3], and a detailed drug/Ecstasy use questionnaire [3], which included five questions on physical and psychological dependence. For the multiple regression analysis, the ecstasy psychological dependence score was created from 3 questions. Finally, a 3 point self-rated item was used as an indication of level of stress the last 6 months (1- More than usual; 2- same as normal; 3 - Less than usual).

RESULTS

Ecstasy users reported higher scores than alcohol/tobacco users on 8 out of 9 BSI subscales. 14% of the Ecstasy user sample met criteria of ecstasy dependence, while 20% had felt dependent on MDMA sometime in their life. Multiple regression identified three main predictors for elevated BSI scores: extent of ecstasy dependence, level of stress experienced in the previous six months and presence of psychiatric disorders in the immediate family, results are displayed in Table 1. In contrast, there was no significant association between Ecstasy dose and regimen variables and the BSI dimensions. There was a significant interaction indicating that level of stress increased global pathology score (GSI) only when the degree of psychological dependence was high (p=0.45).

DISCUSSION

A growing body of evidence [4] has found that common neurobiological pathways and abnormalities may underpin addiction and several psychiatric disorders; this might explain why in this study extent of Ecstasy dependence was strongly associated with elevated psychopathology. Furthermore, stress has been found to be crucial in unmasking vulnerability to both substance use disorders and psychiatric disorders [5]. Accordingly, findings presented here suggest that Ecstasy users who develop Ecstasy dependence might become less able to cope with stress, or it is possible that people who are less able to cope with high levels of stress might be prone to develop Ecstasy dependence. The fact that presence of mental illness in the family was also predictive of elevated psychopathology supports the idea that some people might be predisposed to develop psychological problems following ecstasy use [6, 7].

CONCLUSIONS

Ecstasy psychological dependence was a better predictor of psychological problems than lifetime Ecstasy/MDMA dosage. Those with high levels of Ecstasy dependence were also less able to cope with adverse life events. Pre-existing vulnerability to psychiatric disorders should also be taken into account.

REFERENCES


Received: November 4, 2010 Revised: November 13, 2010 Accepted: November 13, 2010

© Milani et al.; Licensee Bentham Open.
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.